Larimar Therapeutics
Manufacturing · Pennsylvania, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
3 Bala Plz Ste 506, Bala Cynwyd, Pennsyl...Phone Number
(844) 511-9056Website
www.larimartx.comRevenue
-Stock Symbol
LRMRIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About Larimar Therapeutics
Larimar Therapeutics is a clinicalstage biotechnology company that focuses on discovering and developing innovative treatments for complex rare diseases using a proprietary intracellular delivery platform designed to transport therapeutic molecules into cells. The companys core mission centers on addressing serious unmet medical needs by advancing novel protein replacement therapies, with its lead program aimed at treating a debilitating genetic disorder through targeted delivery of a therapeutic protein. Larimar emphasizes rigorous scientific research and collaboration with regulatory authorities and research partners to progress its development programs and expand its pipeline of potential therapies for patients with limited treatment options.Explore more
Larimar Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Larimar Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Larimar Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Larimar Therapeutics
Click to see if Larimar Therapeutics had a recent Job posting/layoffs
Check if Larimar Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Larimar Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Larimar Therapeutics launches new products
Funding: Get notified immidiatlly once Larimar Therapeutics has new funding data
Larimar Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Larimar Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Larimar Therapeutics
Compare insights from companies similar to Larimar Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
51-200
Private
$147.5M
2018
RR
Renuka RamanathanVice President Head of Corporate & Business Development
Company Profile Activity
Activity Insights
Larimar Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Larimar Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Larimar Therapeutics.
Larimar Therapeutics financials insights
Gather financial insights about Larimar Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Stock Offering
$172.5M
Larimar Therapeutics Tech Stack
A closer look at the technologies used by Larimar Therapeutics
See more technologies
Most Recent Scoops
Open Position
Person-Based
Clinical Operations
Open Position
Person-Based
Open Position
Larimar Therapeutics News & Media
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
BALA CYNWYD, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the publication entitled “Nomlabofusp Treatment Produces Frataxin Levels That Correlate Across Peripheral Tissues: Preclinical and Clinical Support for Surrogate Tissue Sampling” in the journal Clinical and Translational Science, an official peer-reviewed publication of the AmerLarimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
*Pro forma cash, cash equivalents, and marketable securities of $244.5 million reflects $136.9 million of cash, cash equivalents and marketable securities as of December 31, 2025 combined with the $107.6 million in net proceeds from the recently completed February 2026 public offering.Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
BALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will present and participate in 1x1 investor meetings at the following upcoming investor conferences taking place in Miami Beach, FL.Deerfield boosts Larimar Therapeutics (LRMR) stake to 34.41% of shares - Stock Titan
Deerfield funds bought Larimar Therapeutics stock at $5.00 per share in a February 2026 offering, lifting their combined holding to 35.67M shares, or 34.41% of the company’s 103.59M shares outstanding.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Larimar Therapeutics
Sign Up For FreeTo access detailed company insights
Larimar Therapeutics is a clinicalstage biotechnology company that focuses on discovering and developing innovative treatments for complex rare diseases using a proprietary intracellular delivery platform designed to transport therapeutic molecules into cells. The companys core mission centers on addressing serious unmet medical needs by advancing... Read More
